This article was originally published in The Rose Sheet
Executive SummarySwiss fragrance and flavors company recently introduced Cosmone, a "novel" fragrance ingredient described as an "intensely rich, powerful and elegant musk," firm announces in first quarter earnings release. Slow retail sales during the 2008 holiday season in North America and Europe led to destocking of fine fragrances in the quarter, resulting in a decline in total fragrance sales of 10.4 percent (5.4 percent in local currencies) to $382.3 million (CHF1=$.87), company reports. Lack of consumer confidence and reduced travel is likely to impact fine fragrance sales throughout 2009, firm notes. Net sales for the period declined 7.3 percent (2.6 percent in local currencies) to $850.7 million, Givaudan reports. Despite first quarter performance, Givaudan expects its total fragrance and flavors businesses will outgrow the underlying market
You may also be interested in...
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.